Condition

BRCA2 Mutation

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 36 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials36

Recruiting8

Common interventions25

Lead sponsors shown15

Clinical trials

36 shown

Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 GeneNCT06817694 · 2026-02-01

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerNCT06201234 · 2024-12-13

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerNCT06488378 · 2024-08-13

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast CancerNCT05485766 · 2024-07-16

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesNCT06395519 · 2024-05-13

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem CellsNCT04150042 · 2021-01-13

Prostate Cancer Genetic Risk Evaluation and Screening StudyNCT05129605 · 2020-02-12

Liquid Biopsy Evaluation and Repository Development at Princess MargaretNCT03702309 · 2017-08-03

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast CancerNCT07499999 · 2026-09-09

NOT_YET_RECRUITING

Study of ACE-86225106 to Treat Patients With Advanced Solid TumorsNCT06380660 · 2024-03-22

ACTIVE_NOT_RECRUITING

Chemo-free BRCA-targeted Neoadjuvant StrategyNCT05209529 · 2024-02-01

Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2NCT05898009 · 2023-10-19

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene AlterationsNCT05498272 · 2023-02-01

ACTIVE_NOT_RECRUITING

Pilot Study of Single-port Robot-assisted Nipple-sparing MastectomyNCT05448963 · 2022-07-30

LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer PatientsNCT05410951 · 2022-05-16

ACTIVE_NOT_RECRUITING

Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer ScreeningNCT04273542 · 2021-05-31

ACTIVE_NOT_RECRUITING

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerNCT03685331 · 2020-10-15

Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate ReconstructionNCT04108117 · 2020-05-14

Genetic Education in BRCA FamiliesNCT03544983 · 2020-05-01

ENROLLING_BY_INVITATION

Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM)NCT04866992 · 2020-02-01

Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing MastectomyNCT04151368 · 2019-11-01

Web-based Family History ToolNCT04890327 · 2019-09-09

The Genetic Education for Men Trial: Web-Based Education vs. Standard CareNCT02957981 · 2018-10-01

Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation TestingNCT03475979 · 2018-05-01

Decision Support for BRCA Testing in Ethnically Diverse WomenNCT03470402 · 2017-12-13

Depression and Body Image Distress Following Mastectomy With ReconstructionNCT03428399 · 2017-10-12

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer PatientsNCT03032614 · 2017-09-30

IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)NCT04012229 · 2017-07-28

Management of Women With BRCA1/2 MutationNCT03211611 · 2017-04-01

Magnetic Resonance Breast Tissue Characterisation to Improve Risk Stratification for Breast CancerNCT03684733 · 2017-03-13

Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 CarriersNCT03495609 · 2016-02-17

Dietary Intervention and BRCA PenetranceNCT03066856 · 2015-12-01

Botulinum Toxin A (Botox) in Tissue Expander Breast ReconstructionNCT01591746 · 2012-08-01

Radical Fimbriectomy for Young BRCA Mutation CarriersNCT01608074 · 2012-01-09

ACTIVE_NOT_RECRUITING

Endocrine Disruptors and Life STILe in Breast Cancer DevelopmentNCT05748353 · 2012-01-01

3.0 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk WomenNCT01409226 · 2009-08-01

Common interventions

Leading sponsors

Dana-Farber Cancer Institute2 Georgetown University2 Massachusetts General Hospital2 University Health Network, Toronto2 858 Therapeutics, Inc.1 Abramson Cancer Center at Penn Medicine1 Acerand Therapeutics (Shanghai) Limited1 Centre Hospitalier Universitaire de Besancon1 Centre Hospitalier Universitaire de la Réunion1 Centre Jean Perrin1 Centre Oscar Lambret1 Chang Gung Memorial Hospital1 CHU de Quebec-Universite Laval1 Columbia University1 European Institute of Oncology1

Trial status mix

COMPLETED14

RECRUITING8

ACTIVE_NOT_RECRUITING5

UNKNOWN3

WITHDRAWN3

ENROLLING_BY_INVITATION1

NOT_YET_RECRUITING1

SUSPENDED1

Phase mix

NA12

PHASE28

PHASE15

PHASE31

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.